<DOC>
	<DOCNO>NCT02946541</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , phase III clinical trial investigate efficacy safety evogliptin oral administration patient type 2 diabetes inadequate glycemic control diet exercise .</brief_summary>
	<brief_title>A Clinical Trial Investigate Efficacy Safety Evogliptin</brief_title>
	<detailed_description>1 . Evogliptin 5mg Group : Administration Evogliptin 5mg 0-52 week . 2 . Placebo Group : Administration Placebo 0-24 week , Evogliptin 5mg 24-52 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects 6.5 % ≤HbA1c≤10.0 % screen Subjects untreated oral hypoglycemic agent within 6 week prior screen Subjects 6.5 % ≤HbA1c≤10.0 % Visit 2 Subjects 20kg/m2≤BMI≤40kg/m2 screening Subjects fast plasma glucose≥270mg/dL screen Patients type 1 diabetes mellitus , secondary diabetes mellitus gestational diabetes mellitus Subjects history myocardial infarction , cerebral infarction within 6 month prior screen Subjects ALT AST 2.5 time high upper normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DA-1229</keyword>
	<keyword>evogliptin</keyword>
	<keyword>DPP-IV inhibitor</keyword>
	<keyword>Suganon</keyword>
	<keyword>DPP-4 inhibitor</keyword>
</DOC>